

---

# HESI Emerging Issues Meeting

---



**B. Bhaskar Gollapudi, PhD**  
The Dow Chemical Company  
Chair, Emerging Issues Steering  
Committee (EISC)

**HESI Annual Meeting**  
**8 June 2011**

---

ILSI Health and  
Environmental Sciences  
Institute

---

# Meeting Goals

---

- ❖ Acknowledge incoming and outgoing Members-at-Large and Scientific Advisors of the HESI Emerging Issues Steering Committee (EISC)
- ❖ Outline the Emerging Issues Process
- ❖ Give report on existing HESI Emerging Issues Subcommittee
- ❖ Explore new topic areas for consideration by HESI constituency



---

---

# 2011 EISC PARTICIPATION



---

# 2011-2012 EISC Leadership

*(to be elected by HESI Assembly of members, 9 June 2011)*

---

## CHAIR:

**Dr. Karen L. Blackburn**

**The Procter & Gamble Company (term expires 2014)**

## VICE CHAIR:

**Dr. Stephen J. Newsholme**

**GlaxoSmithKline (term expires 2016)**

## PAST CHAIR:

**Dr. B. Bhaskar Gollapudi**

**The Dow Chemical Company (term expires 2012)**



---

# 2011 EISC Members-at-Large

*(to be elected by HESI Assembly of members, 9 June 2011)*

---

**Dr. Cynthia A. Afshari** – *newly elected*

Amgen Inc. (term expires 2014)

**Dr. Robert A. Barter** – *newly elected*

ExxonMobil Biomedical Sciences (term expires 2012)

**Dr. Werner H. Bomann**

Bayer CropScience (term expires 2012)

**Dr. Patrick D. Guiney** – *newly elected*

SC Johnson & Son, Inc. (term expires 2014)

**Dr. George Pugh, Jr.**

The Coca-Cola Company (term expires 2013)

**Dr. Mark A. Tirmenstein**

Bristol-Myers Squibb Co. (term expires 2013)

---



---

# 2011 EISC Scientific Advisors

*(to be elected by HESI Assembly of members, 9 June 2011)*

---

**Dr. Darlene Dixon** – re-elected

NIEHS (term expires 2014)

**Dr. Jesse L. Goodman** – newly elected

US FDA (term expires 2014)

**Dr. George Gray** – newly elected

George Washington University (term expires 2014)

**Dr. Toshihisa Ishikawa**

RIKEN Yokohama Institute (term expires 2012)

**Prof. Ian Kimber**

University of Manchester (term expires 2013)

**Dr. James E. Klaunig**

Indiana University (term expires 2013)

**Dr. Derek C.G. Muir**

Environment Canada (term expires 2013)

**Dr. Gary M. Williams**

NY Medical College (term expires 2012)

**Dr. Hal Zenick**

US EPA (term expires 2012)



---

# Outgoing EISC Participants

*(terms ending June 2011)*

---

**Dr. Serrine S. Lau** *(Scientific Advisor)*

University of Arizona

**Dr. Leonard V. Sacks** *(Scientific Advisor)*

US FDA

**Dr. A. Robert Schnatter** *(Member-at-Large)*

ExxonMobil Biomedical Sciences, Inc.

**Dr. James L. Stevens** *(Member-at-Large)*

Eli Lilly and Company



---

---

# EMERGING ISSUES PROCESS





---

# Emerging Issues Process: Issue Identification

---

## Annual Survey:

- ❖ Distributed to HESI stakeholders (membership and a broad cross-section of the international scientific community).
- ❖ In proposing new topics, respondents are asked to consider topics in the context of linkages with issues found on the HESI Scientific Map.
- ❖ Results from the survey are examined by the EISC.
- ❖ Using established criteria, the EISC determines which proposals are presented at the HESI Annual Meeting.
- ❖ After the Annual Meeting, HESI stakeholders vote on the highest priority issue for HESI action that year (*see form in today's meeting packet*).



---

# Criteria for Issue Identification and Prioritization

---

- 1. The issue should be critical for the general scientific community, as well as for current and potential member companies, and should have current public health significance.**
- 2. The issue should have reasonable potential for resolution.**
- 3. The issue should be an area for which HESI has or can identify expertise to contribute.**
- 4. HESI's efforts to address the issue should not be duplicative of other groups.**



---

# Subcommittee Formation and Operation

---

- ❖ Based on voting results (post-Annual Meeting), the EISC selects one emerging issue for HESI action. A Subcommittee is formed.
- ❖ EI projects are resource intensive. Limitations in budget and/or staffing resources may affect adoption or timeline.
- ❖ Funding:
  - **Year One:** \$50,000 in funding from HESI; no fees for participation.
  - **Year Two:** HESI matches funding raised by committee up to \$50,000.
  - **Beyond Year Two:** If desired, participants petition HESI Board for Project or Technical Committee status; project is then funded entirely by participant dollars.



---

---

# EXISTING EMERGING ISSUES SUBCOMMITTEE



---

# Subcommittee Report

---

## Evaluating causality in epidemiologic studies

**Dr. A. Robert Schnatter**

**(ExxonMobil Biomedical Sciences, Inc.)**

**Subcommittee Steering Team Member**



---

---

# NEW TOPIC PRESENTATIONS

**ONE TOPIC WILL BE SELECTED  
FOR HESI ACTION IN 2011.**



---

# New Topic Presentations

---

**Modeling the environmental impact from water withdrawal and disposal across the life cycle of products**

**Dr. Jennifer Orme-Zavaleta (US EPA)**

**Mr. Gert van Hoof (Procter & Gamble)**

**Frameworks for alternative chemical assessment and selection of safer, sustainable alternatives**

**Dr. P. Robert Peoples (ACS Green Chemistry Institute)**

**Dr. Robert Barter (ExxonMobil Biomedical Sciences)**

**Dr. Pamela Spencer (Dow Chemical Company)**

---



---

# **New Topic Presentations, cont'd.**

---

**Alveolar macrophage changes in response to inhaled drugs: factors distinguishing adaptive from adverse effects**

**Dr. Jan Klapwijk (GlaxoSmithKline)**

**Dr. Darlene Dixon (NIEHS)**

**Human iPS/ES cell technology and its application to toxicology testing, especially focusing on in vitro cardiac function toxicity**

**Prof. Kenji Yasuda (Tokyo Medical and Dental University)**

**Dr. Atsushi Sanbuissho (Daiichi Sankyo Co., Ltd.)**

